Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CVRx (CVRX)
NASDAQ:CVRX
Holding CVRX?
Track your performance easily
CVRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.40 - $33.14
Previous Close$12.11
Volume299.71K
Average Volume (3M)285.42K
Market Cap
$293.83M
Enterprise Value$243.84M
Total Cash (Recent Filing)$100.16M
Total Debt (Recent Filing)$50.16M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Jan 23, 2025EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.71
Shares Outstanding24,263,663
10 Day Avg. Volume166,493
30 Day Avg. Volume285,424
Standard Deviation0.28
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)4.50
Price to Sales (P/S)6.22
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.16
Enterprise Value/Gross Profit7.38
Enterprise Value/Ebitda-4.35
Forecast
1Y Price Target
$18.20Price Target Upside50.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
CVRx News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCVRx reported Q3’24 revenue of $13.4M (+27% Y/Y), above the Street at $13.2M, with core HF revenue up 30% Y/Y.
Market OpportunityCVRx's Barostim fulfills a clinical unmet need in an unpenetrated $2.2B annual incidence market.
ReimbursementThe CMS panel unanimously voted in favor of maintaining reimbursement at the $45K level, which is expected to be a significant catalyst for CVRx shares.
Bears Say
Financial PerformanceEPS of ($0.57) was lower than expected, driven by higher compensation and headcount expenses.
Regulatory ChallengesThere is a possibility that CMS may move CVRX to a level 5 neurostimulator code, potentially decreasing Barostim’s reimbursement from $45K to ~$31.2K.
Revenue ForecastThe company lowered its 2025 revenue estimates based on management commentary.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $6.40 and its highest was $33.13 in the past 12 months.
What is CVRx’s market cap?
Currently, no data Available
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Jan 23, 2025 which is in 31 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on Oct 29, 2024. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.504 by -$0.066.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -$0.38.
How many shares outstanding does CVRx have?
CVRx has 24,263,662 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.504. Following the earnings report the stock price went up 31.006%.
Which hedge fund is a major shareholder of CVRx?
Among the largest hedge funds holding CVRx’s share is Mairs & Power Inc. It holds CVRx’s shares valued at 1M.
---
CVRx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.20 (50.29% Upside)
$18.20 (50.29% Upside)
Blogger Sentiment
Neutral
CVRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 4.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.22%
12-Months-Change
Fundamentals
Return on Equity
-79.02%
Trailing 12-Months
Asset Growth
19.99%
Trailing 12-Months
Company Description
CVRx
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.
---
CVRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and significant reimbursement wins, particularly in the U.S. market, alongside expansion in implanting centers and a robust cash position. However, challenges included increased operating expenses and a rise in net loss and interest expenses. The company remains optimistic about future growth and adoption of its Barostim therapy.Read More>---
CVRX Stock 12 Month Forecast
Average Price Target
$18.20
▲(50.29% Upside)
Technical Analysis
Best Analysts Covering CVRX
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+21.94%
reiterated a buy rating 2 months ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +21.94% per trade.
---